Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Randomized, Open-Label 2x2 Factorial Study to Compare the Safety and Efficacy of Different Combination Antiretroviral Therapy Regimens in Treatment Naive Patients With Advanced HIV Disease and/or CD4+ Cell Counts Less Than 200 Cells/MicroL

Next Previous
Trial Profile

Randomized, Open-Label 2x2 Factorial Study to Compare the Safety and Efficacy of Different Combination Antiretroviral Therapy Regimens in Treatment Naive Patients With Advanced HIV Disease and/or CD4+ Cell Counts Less Than 200 Cells/MicroL

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 03 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Didanosine (Primary) ; Efavirenz (Primary) ; Lopinavir/ritonavir (Primary) ; Stavudine (Primary) ; Zidovudine (Primary) ; Antiretrovirals; Lamivudine; Lamivudine/stavudine
  • Indications HIV infections
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms PHIDISA II

    • Most Recent Events

    • 18 Jun 2011 Results of a subgroup analysis reporting the prevalence of NNRTI drug resistance mutations in patients who achieved viral load <400 copies/mL at 6 months but subsequently had 2 consecutive measures of >1000 copies/mL have been reported in JAIDS.
    • 13 Oct 2010 Results were published in the Journal of Infectious Diseases.
    • 19 Feb 2010 Results of a sub-study of genotypic resistance at viral rebound have been reported at the 17th Conference on Retroviruses and Opportunistic Infections (CROI 2010).
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top